Taiwan FDA registration c89aefec4e483f19dc87ea1e7a936b71

"Leica" Bond Ready-to-Use Primary Antibody CD138 (MI15)(Non-Sterile)

TW: “錸卡”邦德即用型細胞標誌138一級抗體(MI15)(未滅菌)

Taiwan·Risk Class 1·MD·LEICA BIOSYSTEMS NEWCASTLE LTD.·Registered Nov 26, 2018 – Nov 26, 2028Active

Registration details

Analysis ID: c89aefec4e483f19dc87ea1e7a936b71
License Form: Ministry of Health Medical Device Import No. 019852
Customs Code: DHA09401985200

Company information

Manufacturer: LEICA BIOSYSTEMS NEWCASTLE LTD.
Manufacturer Country: United Kingdom
Authorized Representative: BECKMAN COULTER TAIWAN INC., TAIWAN BRANCH (U.S.A.)

Product details

Intended Use: Limited to the first level identification range of immunopathological histochemical reagents and kits (B.1860) of the Measures for the Administration of Medical Devices.
Product Type (Level 1): B Hematology and pathology devices
Product Type (Level 2): B1860 Immunopathological histochemical reagents and kits
Import Information: Imported from abroad

Dates and status

Registration Date: Nov 26, 2018
Expiry Date: Nov 26, 2028

About this record

Access comprehensive regulatory information for "Leica" Bond Ready-to-Use Primary Antibody CD138 (MI15)(Non-Sterile) in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 1 medical device is registered under number c89aefec4e483f19dc87ea1e7a936b71 and manufactured by LEICA BIOSYSTEMS NEWCASTLE LTD.. The authorized representative in Taiwan is BECKMAN COULTER TAIWAN INC., TAIWAN BRANCH (U.S.A.).

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.